Fmi2 inhibitors are a class of chemical compounds designed to interfere with the function of the Fmi2 protein, which plays a role in various cellular processes. The Fmi2 protein, often a part of signaling pathways, can influence cellular communication, growth, and development. Inhibitors targeting Fmi2 often exhibit specific binding affinities that allow them to modulate the activity of the protein, impacting how it interacts with other cellular components. These inhibitors are typically designed to target the protein's active site or other key regulatory domains, preventing Fmi2 from performing its normal functions within the cell. The inhibition process usually involves competitive or allosteric binding mechanisms that disrupt the protein's conformational state or its ability to bind to other molecules.
The chemical structures of Fmi2 inhibitors are diverse, often featuring heterocyclic cores, which provide the necessary scaffold for binding interactions. Some inhibitors may contain functional groups that enhance solubility, stability, or bioavailability, ensuring that the compound remains active in biological environments. Structural variations are introduced to optimize their specificity and minimize off-target effects. The inhibitors may also possess properties like chirality, allowing for selective interaction with the Fmi2 protein. Advanced techniques such as structure-activity relationship (SAR) analysis are used to refine these molecules, enabling more efficient design. The development of Fmi2 inhibitors can be highly systematic, involving computational modeling, high-throughput screening, and iterative chemical modifications to enhance their inhibitory potency and selectivity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939 inhibits Wnt/β-catenin signaling, potentially impacting pathways associated with CELSR1. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
IWP-2 inhibits Wnt production, potentially modifying the PCP pathway and indirectly affecting CELSR1. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $214.00 $326.00 $1275.00 | 1 | |
LGK-974 is a Wnt secretion inhibitor, which could indirectly influence CELSR1-related pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, may have indirect effects on CELSR1 through MAPK/ERK pathway modulation. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine, a Hedgehog pathway inhibitor, might indirectly affect CELSR1, given the crosstalk between PCP and Hedgehog signaling. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT, a Notch pathway inhibitor, could influence pathways that intersect with CELSR1's role in cell polarity and development. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, could indirectly affect CELSR1 through PI3K/AKT pathway interactions with Wnt/PCP signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, might indirectly influence processes related to CELSR1 through mTOR pathway modulation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, an inhibitor of TGF-β receptors, might affect cellular processes where CELSR1 is involved due to TGF-β signaling interactions. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $82.00 $158.00 | 1 | |
Vismodegib, a Hedgehog pathway inhibitor, could have indirect effects on CELSR1 activity through pathway crosstalk. | ||||||